[Cardiology 2009].
Hoppe
U C
UC
Klinik III für Innere Medizin, Universität zu Köln, Kerpener Strasse 62, 50937 Köln. Uta.Hoppe@uni-koeln.de
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002309:Cardiology / Q000639:trends*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics / Q000517:prevention & control*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D015444:Exercise; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D013318:Stroke Volume; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine